AAD 2024 Highlights Podcast

In this episode [14.28], Medicom’s correspondent covers 6 presentations from the annual meeting of the American Academy of Dermatology (AAD 2024), held in San Diego, CA, USA, from 8-12 March 2024.
The topics discussed are:

1. BTK inhibition - a novel approach to HS treatment
   The selective Bruton’s tyrosine kinase inhibitor remibrutinib was investigated as therapy for hidradenitis suppurative (HS). The phase 2 results show promise in efficacy and safety for this new treatment target in HS.
2. Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells
   In the KNOCKOUT trial, high induction doses of the IL-23 blocker risankizumab led to a marked reduction in resident memory T cells even 36 weeks after application of the last dose. This might explain the long durability of skin clearance seen in psoriasis patients treated with an IL-23 inhibitor.
3. Delgocitinib cream: finally a promising treatment option for chronic hand eczema?
   A long-term extension of chronic hand eczema treatment with delgocitinib cream led to favourable findings for safety and efficacy in the phase 3 DELTA 3 trial. The rate of participants with an Investigator’s Global Assessment of 0/1 further increased over time, while no new safety signals were observed.
4. Botanical drug solution: a novel way to treat AA in children and adolescents
   Twice daily treatment with a solution containing plant extracts led to sustained hair regrowth and improvement in quality of life in children and adolescents with alopecia areata. Of note, Severity of Alopecia Tool (SALT) score improved even in the 24 weeks following coacillium treatment discontinuation.
5. Upadacitinib: a novel treatment possibility for vitiligo
   In a phase 2 trial, the JAK1 inhibitor upadacitinib led to a fast improvement in repigmentation in patients with non-segmental vitiligo. After the 24-week, double-blind phase, participants showed continuous further pigmentation both in the face and the body.
6. JAK1 inhibitor meets primary endpoint in prurigo nodularis
   Povorcitinib outperformed placebo in treating prurigo nodularis. More than half of the participants in this phase 2 trial achieved a ≥4-point improvement in itch on the numeric rating scale on the highest study dose of povorcitinib.

Enjoy listening!

Copyright ©2024 Medicom Medical Publishers



Posted on 24 March 202427 June 2024